decreased in AB cardiomyocytes with increasing pacing frequency, revealing a negative shortening-frequency relationship that was attenuated by both drug treatments. Length:width ratio was decreased in AB and AB-TAD animals with commensurate decreases in left ventricular (LV) end diastolic and end systolic volumes. Normal cardiomyocyte size and LV volumes were preserved in the AB-SAX group. Interestingly, all AB groups exhibited similar gross hypertrophic remodeling (heart weight:body weight ratio) despite differences in cardiomyocyte morphology. In conclusion, saxagliptin appears superior for preserving normal cardiomyocyte morphology and overall function versus tadalafil, independent of changes in cGMP-PKG activity. Quercetin (3, 3 0 , 4 0 , 5, 7-pentahydroxyflavone, QCT) is a major flavonoid of plants, known to exhibit anti-oxidative, anti-inflammatory, and anti-cancer effects. QCT has been demonstrated to have a cardioprotective effect through its antioxidant activity. In the present study, we found that QCT markedly enhanced the contractility of a single cardiomyocyte isolated from mouse hearts in a dynamic fashion even under conditions with no apparent oxidative stress. Simultaneous measurement of Ca 2þ transient in a Fura-2 loaded single cardiomyocyte revealed that QCT markedly increased the cytoplasmic Ca 2þ both at diastole and systole under regular electrical stimulation. Echocardiography revealed that intravenous administration of QCT also increased the left ventricular systolic function of the heart evaluated by ejection fraction in mice with reduced cardiac function due to a mutation causing genetic dilated cardiomyopathy (delK210 mutation in cardiac troponin T). QCT did not change the maximum force-generating capability and Ca 2þ sensitivity of force generation in skinned (membrane-permeabilized) cardiac muscle fibers prepared from mouse hearts, indicating that QCT has no direct effects on the contractile machinery in cardiomyocytes. These findings indicates that QCT has a direct cardiotonic effect through enhancing the Ca 2þ transient in cardiomyocytes independently of its antioxidative action. Studies on the molecular mechanisms underlying these phenomena are in progress.
1 Imperial College, London, United Kingdom, 2 Nanyang Technological University, Singapore, Singapore. We examined the relationships between troponin I phosphorylation and Ca 2þregulation of contractility in single myofibrils from a mouse model of familial DCM (ACTC E361G) in comparison with non-transgenic (NTG) . We measured the effects of changing [Ca 2þ ] and troponin I phosphorylation level on myofibril contractility. Propranolol treatment of mice was used to reduce the level of troponin I in their hearts prior to isolating the myofibrils. For non-transgenic mouse myofibrils we found that when the TnI phosphorylation level was reduced from 1.02 to 0.3 the Ca 2þ -sensitivity of force was increased (EC 50 P/unP¼1.8), relaxation parameter k REL was reduced and t LIN was increased. ACTCE361G mouse myofibrils were uncoupled: Ca 2þ -sensitivity and relaxation parameters did not depend on troponin I phosphorylation level (EC 50 P/unP¼0.88). Nevertheless, modulation of Ca 2þ -sensitivity by sarcomere length or due to EMD57033 was retained. The Ca 2þ -desensitiser Epigallocatechin-3-gallate (EGCG) decreased Ca 2þsensitivity in phosphorylated and unphosphorylated NTG myofibrils equally (EC50 P/uP¼ 0.5050.06 and 0.4550.07 respectively) but did not change the relaxation parameters t LIN and k RE . The rate of force development (k ACT ), measured at high Ca 2þ , was unchanged in myofibrils with phosphorylated TnI and 22% decreased in unphosphorylated myofibrils indicating that EGCG affects cross-bridge activation kinetics. EGCG reduced Ca 2þ -sensitivity and k ACT in both phosphorylated and unphosphorylated ACTCE361G myofibrils. The change in EC 50 was more in phosphorylated than unphosphorylated myofibrils, consequently EGCG restored the lost difference in EC 50 values between phosphorylated and unphosphorylated myofibrils and also the difference in relaxation parameters t LIN and k REL . The observation that EGCG does not affect either the EC 50 P/ EC 50 unP or t LIN in NTG myofibrils but changes them in ACTG E361G suggests that EGCG can restore modulation of cardiac contractile function by TnI phosphorylation to DCM mutant myofibrils independently of its Ca 2þ -desensitising function. Whole exon sequence data from 28 FDCM patient cardiac muscle samples was screened for potentially disease-causing mutations in 58 genes previously implicated in HCM or DCM . We identified OBSCN gene mutations in 5 samples; one sample had two OBSCN mutations, one also had a DSP mutation and another also had a SCN5A mutation Also identified were 6 truncating mutations in TTN, 3 mutations in MYH7, 2 in DSP and one each in TNNC1, TNNI3, MYOM1, VCL, GLA, PLB, PKP2 and LAMA4 . The mean level of obscurin mRNA was significantly greater and more variable in donor samples than the FDCM samples (1.6950.53, n¼58 compared with 0.5750.10,n¼ 68, p¼0.0025). The mRNA content of FDCM samples was not significantly different with and without OBSCN mutations. The obscurin protein band was estimated to be <1% of the abundance of titin; it was identified and quantified with antibodies. The apparent mass was 9605 60 kDa. The OBSCN mutation samples had levels of expression, significantly different from FDCM samples without obscurin mutations, donor hearts or myectomies. Four OBSCN mutant samples exhibited low levels of obscurin protein (48, 61, 51,and 70% of the level in control FDCM samples). One OBSCN mutant sample exhibited 34% more expression. Immunofluorescence microscopy using obscurin, myomesin and a-actinin-specific antibodies showed that obscurin was located at the level of the M-line and preferentially labelled the sides of the myofibrils. There was no apparent differences between wild-type and mutant samples. Mutations in the obscurin gene should be considered as a significant cause of FDCM, alone or in concert with another mutation. Disease-related OBSCN mutations cause demonstrably abnormal expression in myofibrils that could account for the development of a DCM phenotype.
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1466-Pos Board B417 Differential Involvement of Various Sources of Reactive Oxygen Species in Thyroxin-Induced Hemodynamic Changes and Contractile Dysfunction of the Heart and Diaphragm Muscles
Mohammad T. Elnakish 1,2 , Eric J. Schultz 1 , Rachel L. Gearinger 1 , Nancy S. Saad 1,2 , Neha Rastogi 1 , Amany A.E. Ahmed 2 , Peter J. Mohler 1 , Paul M.L. Janssen 1 . 1 The Ohio State University, COLUMBUS, OH, USA, 2 Helwan University, Helwan, Cairo, Egypt. Thyroid hormones are key regulators of basal metabolic state and oxidative metabolism. Hyperthyroidism has been reported to cause significant alterations in hemodynamics, and cardiac and diaphragm muscle function, all which have been linked to increased oxidative stress. Previously, we have shown that thyroxin (T4) treatment in mice resulted in hypertension, increased cardiac reactive oxygen species (ROS), cardiac hypertrophy, and cardiac contractile dysfunction. Here, we sought to investigate the functional impact of T4 on diaphragm muscle function as well as to identify the role and the source(s) of ROS in these distinct phenotypes of our model. Wild-type and T4 mice with and without 2-week treatments with allopurinol (xanthine oxidase inhibitor), apocynin (NADPH-oxidase inhibitor), L-NIO (nitric oxide synthase inhibitor), or MitoTEMPO (mitochondria-targeted antioxidant) were studied. Blood pressure and echocardiography were non-invasively evaluated, followed by ex-vivo assessments of isolated heart and diaphragm muscle functions. Treatment with L-NIO attenuated the T4-induced hypertension in mice. However, apocynin improved the left ventricular (LV) dysfunction without preventing the cardiac hypertrophy in these mice. Both allopurinol and MitoTEMPO reduced the T4-induced fatigability of the diaphragm muscles. In conclusion, we show here for the first time that T4 exerts differential effects on various sources of ROS to induce distinct cardiovascular and skeletal muscle phenotypes. Additionally, we find that T4-induced LV dysfunction is independent of cardiac hypertrophy, while NADPH-oxidase is a key player in this process. Furthermore, we prove the significance of both xanthine-oxidase and mitochondrial ROS pathways in T4-induced fatigability of diaphragm muscles.
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